We present a rare case of IgA nephropathy in a patient who developed atypical hemolytic uremic syndrome (aHUS) associated with a complement factor H (CFH) gene mutation, and who was successfully treated with eculizmab. A 76-year-old man was admitted as the patients had thrombotic microangiopathies findings. The patient was treated with plasma exchange, hemodialysis and methylprednisolone. A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 level was not decreased. Light microscopy findings were consistent with hemolytic uremic syndrome and immunofluorescence analysis revealed IgA and C3 were detected. Genetic analysis revealed that mutation of p.Arg1215Gln in CFH was identified. The diagnosis of aHUS was confirmed and eculizmab therapy was currently effective for 5 months.

Keywords:
Hemolytic anemia, Thrombocytopenia, Complement C3
1.
Moake JL: Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002; 126: 1430–1433.
2.
Noris M, Remuzzi G: Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676–1687.
3.
Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ: Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010; 31:E1445–E160.
4.
Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C: Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013; 28: 2246–2259.
5.
Morita S, Sakai T, Okamoto N, Funabiki A, Okada Y, Hasegawa Y, Amano K, Yoshikawa N, Kasuga M: Hemolytic uremic syndrome associated with immunoglobulin A nephropathy. A case report and review of cases of hemolytic uremic syndrome with glomerular disease. Intern Med 1999; 38: 495–499.
6.
Wang R, Zhang Y, Li S, Chen H, Zeng C, Chen H, Tang Z, Liu Z: Hemolytic uremic syndrome complicated with IgA nephropathy: a case report and literature review. Clin Nephrol 2015; 83: 36–40.
7.
El Karoui K, Hill GS, Karras A, Jacquot C, Moulonguet L, Kourilsky O, Frémeaux-Bacchi V, Delahousse M, Duong Van Huyen JP, Loupy A, Bruneval P, Nochy D: A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012; 23: 137–148.
8.
Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y: A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One 2015 7; 10:e0124655.
9.
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844–1859.
10.
Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF: Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181–1190.
11.
Oortwijn BD, Eijgenraam JW, Rastaldi MP, Roos A, Daha MR, van Kooten C: The role of secretory IgA and complement in IgA nephropathy. Semin Nephrol 2008; 28: 58–65.
12.
Schmitt R, Krmar RT, Kristoffersson A, Söderberg M, Karpman D: IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr 2011; 170: 107–110.
13.
Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, Liu LJ, Lv JC, Yu F, Zhao MH, Zhang H: Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J Am Soc Nephrol. 2016; 27: 2894–2905.
14.
Tortajada A, Gutiérrez E, Goicoechea de Jorge E, Anter J, Segarra A, Espinosa M, Blasco M, Roman E, Marco H, Quintana LF, Gutiérrez J, Pinto S, Lopez-Trascasa M, Praga M, Rodriguez de Córdoba S: Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy. Kidney Int 2017; 92: 953–963.
15.
Ring T, Pedersen BB, Salkus G, Goodship TH:Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 2015; 8: 489–491.
16.
Herzog AL, Wanner C, Amann K, Lopau K: First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation: a case report. Transplant Proc 2017; 49: 1574–1577.
17.
Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E: Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 1312–1316.
18.
Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M: Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 2014; 64: 633–637.
19.
Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V: Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014; 63: 40–48.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.